FINWIRES · TerminalLIVE
FINWIRES

Research Alert: J Mar-q: Strong Eps Beat Driven By Broad-based Growth And Record Backlog

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

J delivered strong Mar-Q results with adjusted EPS of $1.75 vs. $1.43 prior year, beating Street estimate of $1.63, while adjusted net revenue of $2.3B (+9%) marked accelerating growth momentum. The Infrastructure & Advanced Facilities segment showed robust performance at $1.97B (+8%) with Critical Infrastructure +9%, Water & Environmental +2%, and Life Sciences & Advanced Manufacturing +12%, while PA Consulting continued impressive trajectory with 17% growth. This diversified performance underscores J's successful positioning across high-growth, high-margin sectors benefiting from secular tailwinds. The completion of PA Consulting acquisition represents a strategic milestone, with management increasing cost synergy estimates to $20M+ within 24 months from the initial $16M-$20M range. J's record backlog of $27.0B (+22%) provides exceptional revenue visibility, supported by strong book-to-bill ratios of 1.2x for Mar-Q and 1.4x trailing-12-month.

Related Articles

Asia

Cofoe Medical Technology Nets HK$1 Billion From Hong Kong IPO Ahead of Debut

Cofoe Medical Technology (HKG:1187, SHE:301087) raised HK$1.01 billion in net proceeds from its initial public offering in Hong Kong.The offer price was set at HK$39.33 per H-share, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.The China-based home care medical device provider offered 27 million H-shares in the global offering.The Hong Kong public offer was 399.08 times subscribed, with 2.7 million shares allocated, representing 10% of the total offering.The international offering was 3.4 times subscribed, with 24.3 million shares allocated, accounting for 90% of the total offering.Cornerstone investors, including Lens Technology (HK), Changsha Yufeng Technology, Vision Capital, and Panjing Harbourview Investment Fund, were allocated about 9.7 million shares in the international tranche, according to the filing.Cofoe Medical is scheduled to begin trading in Hong Kong on Wednesday, May 6.

$HKG:1187$SHE:301087
Insider Trading

Cytokinetics Insider Sold Shares Worth $270,795, According to a Recent SEC Filing

Fady Ibraham Malik, Executive Vice President, Research & Development, on May 05, 2026, sold 3,500 shares in Cytokinetics (CYTK) for $270,795. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000051/xslF345X05/form4.xml

$CYTK
Mining & Metals

Correction: -- Pan American Silver Targets Up to US$1B in Shareholder Returns in 2026 Through Enhanced Shareholder Return Framework

$PAAS.TO